Tablet Presentation

Each uncoated tablet contains:
Repaglinide IP 0.5 mg

Repaglinide is the oral hyperglycemic drug, belongs to the class of meglitinide analogues. It is used for non – insulin dependent diabetes mellitus. It helps to reduces postprandial sugar.

Therapeutic Indication

Diabetes mellitus

Mechanism of Action

Repaglinide acts on the beta cells and blocks the ATP sensitive potassium channel and causes depolirization and open up the calcium channel, calcium causes degranulation of insulin thus increases insulin sensitivity

Pharmacokinetics

Absorption- It is completely absorbed by oral route
Protein binding- It is about 98% bound to the plasma proteins mainly to albumin and alpha acid glycoprotein
Metabolism– It undergoes oxidation and dealkylation
Excretion- Mainly excreted via feces and to a lesser extent by urine

Side Effects

• Weight gain
• Diarrhea
• Joint pain
• hypoglycemia

Contraindication

• Contraindicated in pregnancy
• Contraindicated in patients with known hypersensitivity

Storage

Store it at room temperature.